Refine your search
Collections
Co-Authors
- Kinjal Modi
- Smita Mahale
- Nutan Nabar
- D. B. A. Narayana
- Ashwinikumar Raut
- Sanjiv Shah
- Bhushan Patwardhan
- Ashok Vaidya
- Hiteshi Dhami
- Madhura Kulkarni
- Kalpana Dhuri-Shah
- Jayashree Joshi
- Sujata Jagatap
- Deepak Dave
- Hemant Paradkar
- Jaya Gogate
- Susan Sodder
- Lal Hingorani
- Dilip Mehta
- Ashok B. Vaidya
- Narendra Nath Mehrotra
- Ashok DB Vaidya
- Beena Joshi
- Gazala Hasan
- Gulrez Tyebkhan
- Shobha Udipi
- Anushree Patil
- Duru Shah
- Madhuri Patil
- Roda Dalal
- Kanchan Kaur
- Anand Shindikar
- Anushree Mehta
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Vaidya, Rama
- Antenatal Screening for HIV Infection and Prevention of Parent to Child Transmission
Abstract Views :182 |
PDF Views:0
Authors
Affiliations
1 Unit of Endocrine and Metabolic Disorders, MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
1 Unit of Endocrine and Metabolic Disorders, MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 726-727Abstract
No AbstractKeywords
No Keywords
- Medi News
Abstract Views :179 |
PDF Views:0
Authors
Affiliations
1 Unit of Endocrine and Metabolic Disorders, MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
1 Unit of Endocrine and Metabolic Disorders, MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 729-741Abstract
No AbstractKeywords
No Keywords- Medi Quiz
Abstract Views :189 |
PDF Views:0
Authors
Affiliations
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 779-781Abstract
No AbstractKeywords
No Keywords- Medi Matters
Abstract Views :171 |
PDF Views:0
Authors
Affiliations
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400056, IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 789-790Abstract
No AbstractKeywords
No Keywords- Ayush
Abstract Views :165 |
PDF Views:0
Authors
Affiliations
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400 056, IN
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400 056, IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 791-792Abstract
No AbstractKeywords
No Keywords- Nutraceuticals
Abstract Views :190 |
PDF Views:0
Authors
Affiliations
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400 056., IN
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400 056., IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 793-793Abstract
No AbstractKeywords
No Keywords- Medi Events
Abstract Views :205 |
PDF Views:1
Authors
Affiliations
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400 056, IN
1 MRC KHS, Sthanakwasi Jain Aradhanadham, K. D. Road, Vile Parle (w). Mumbai 400 056, IN
Source
The Indian Practitioner, Vol 67, No 12 (2014), Pagination: 794-794Abstract
No AbstractKeywords
No Keywords- Obesity and Metabolic Syndrome: Debated Risk Factors for Prostate Diseases
Abstract Views :183 |
PDF Views:0
Authors
Affiliations
1 Unit of Endocrine and Metabolic Disorder, MRC KHS, Sthanakwasi Jain Aradhana Dham, K. D. Road, Vile Parle (W), Mumbai 400 056, IN
1 Unit of Endocrine and Metabolic Disorder, MRC KHS, Sthanakwasi Jain Aradhana Dham, K. D. Road, Vile Parle (W), Mumbai 400 056, IN
Source
The Indian Practitioner, Vol 67, No 7 (2014), Pagination: 403-404Abstract
No Abstract.- Non-Cystic Fibrosis Bronchiectasis: Is Early Diagnosis Missed?
Abstract Views :238 |
PDF Views:0
Authors
Rama Vaidya
1,
Kinjal Modi
2
Affiliations
1 Unit of Endocrine and Metabolic Disorders, MRC,KHS, Stanakwasi Jain Aradhana Dham, KD Road, Vile Parle (W), Mumbai 400 056, IN
2 DNB, FCCP, US
1 Unit of Endocrine and Metabolic Disorders, MRC,KHS, Stanakwasi Jain Aradhana Dham, KD Road, Vile Parle (W), Mumbai 400 056, IN
2 DNB, FCCP, US
Source
The Indian Practitioner, Vol 68, No 4 (2015), Pagination: 6-7Abstract
No Abstract.- Women's Health Burden in India: a Daunting Challenge
Abstract Views :210 |
PDF Views:0
Authors
Rama Vaidya
1,
Smita Mahale
2
Affiliations
1 Unit of Endocrine and Metabolic Disorders, Kasturba Health Centre-Medical Research Centre, IN
2 National Institute for Research in Reproductive Health (NIRRH), Opposite Ramesh Bhuvan, J Merwanji St, Parel East, Mumbai, Maharashtra 400012, IN
1 Unit of Endocrine and Metabolic Disorders, Kasturba Health Centre-Medical Research Centre, IN
2 National Institute for Research in Reproductive Health (NIRRH), Opposite Ramesh Bhuvan, J Merwanji St, Parel East, Mumbai, Maharashtra 400012, IN
Source
The Indian Practitioner, Vol 68, No 7 (2015), Pagination: 7-8Abstract
No Abstract.- Postpartum Thyroiditis Vs Postpartum Blues/Depression: a Mini Review
Abstract Views :167 |
PDF Views:0
Authors
Affiliations
1 Vasudha Clinic, Saraswati Rd. Sahtacruz (W),Mumbai 400054, IN
1 Vasudha Clinic, Saraswati Rd. Sahtacruz (W),Mumbai 400054, IN
Source
The Indian Practitioner, Vol 66, No 8 (2013), Pagination: 500-501Abstract
No Abstract.- Marketed Ayurvedic Antidiabetic formulations: Labeling, Drug Information and Branding
Abstract Views :278 |
PDF Views:0
Authors
Nutan Nabar
1,
Rama Vaidya
2,
D. B. A. Narayana
3,
Ashwinikumar Raut
4,
Sanjiv Shah
4,
Bhushan Patwardhan
5,
Ashok Vaidya
4
Affiliations
1 Symbiosis International University, Pune, IN
2 Kasturba Health Society's Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine Medical Research Center-KHS, 17, Khandubhai Desai Road, Vile Parle (West), Mumbai 400 056, IN
3 Ayurvidye Trust, Bangalore, IN
4 Kasturba Health Society's Medical Research Centre, Mumbai, IN
5 The Interdisciplinary School of Health Sciences, Pune, IN
1 Symbiosis International University, Pune, IN
2 Kasturba Health Society's Medical Research Centre, ICMR Advanced Centre for Reverse Pharmacology in Traditional Medicine Medical Research Center-KHS, 17, Khandubhai Desai Road, Vile Parle (West), Mumbai 400 056, IN
3 Ayurvidye Trust, Bangalore, IN
4 Kasturba Health Society's Medical Research Centre, Mumbai, IN
5 The Interdisciplinary School of Health Sciences, Pune, IN
Source
The Indian Practitioner, Vol 66, No 10 (2013), Pagination: 631-639Abstract
Diabetic patients, in India are known to take one or more Marketed Ayurvedic Antidiabetic Formulations (MAAF) alone or with the conventional drug/s as over the counter or through self medication. The labeling information is crucial for patient information and safety besides fulfilling the regulatory needs. for drugs from any system of medicine. The present study was aimed at to study MAAF for patient information, regulatory compliance and patient safety.The labels of 180 MAAF were analysed as to the details of brand names, dosage forms, ingredients, composition, dosage schedule and precautions. Package inserts of additional fifty three MAAFs were reviewed for the compliance.
The ingredients used in the products varied widely, as to the plants' identity, parts and extracts used and their concentrations. The dosage of the ingredients ranged from a few mgs to 2-3 gms, depending on raw herbs or extracts used. The current labels, studied for the composition details, did not clearly indicate the quantity of each ingredient to the original raw herb quantum. There was a wide variation in the way composition was printed on the label. The study shows a need for improvement in compliance to labeling regulations. There was no information about the suitability of these drug's administration in pregnancy and/or lactation.,or specific dose and drug formulation for paediatric and geriatric groups.
Brand names studied have chiefly reflected antidiabetic/Madhumehaghna activity. However, some of the brand names like Sugar Knocker, Sugar balance etc convey exaggerated claims. Drug regulators may continue to license MAAF with brand names but sanction those that could be misleading. Ayurvedic manufacturers need to consider and register their trade names under Trade Mark Registration Act to avoid duplicity and misuse of same names, across the state of India.
Keywords
Ayurvedic Antidiabetic Medicine, Ayurvedic Pharmacoepidemiology, Drug Regulation, Brand Names, Labeling and Package Inserts, MAAF.- Non Alcoholic Fatty Liver Disease (NAFILD) an Emerging Public Health Challenge
Abstract Views :162 |
PDF Views:0
Authors
Source
The Indian Practitioner, Vol 66, No 4 (2013), Pagination: 190-191Abstract
No Abstract.- Vitamin D Deficiency: A Public Health Challenge
Abstract Views :185 |
PDF Views:0
Authors
Affiliations
1 Unit of Endocrine and Metabolic Disorders, Kasturba Health Centre- Medical Research Centre. Consultant Reproductive Endocrinologist, Vasudha Clinic, Santacruz, Mumbai, IN
1 Unit of Endocrine and Metabolic Disorders, Kasturba Health Centre- Medical Research Centre. Consultant Reproductive Endocrinologist, Vasudha Clinic, Santacruz, Mumbai, IN
Source
The Indian Practitioner, Vol 68, No 12 (2015), Pagination: 7-8Abstract
No Abstract.- Sleep Debt Epidemic of 21st Century
Abstract Views :208 |
PDF Views:1
Authors
Affiliations
1 Unit of Endocrine and Metabolic Disorders, Kasturba Health Centre- Medical Research Centre, IN
1 Unit of Endocrine and Metabolic Disorders, Kasturba Health Centre- Medical Research Centre, IN
Source
The Indian Practitioner, Vol 69, No 6 (2016), Pagination: 7-8Abstract
No Abstract.- Scope of Ayurceuticals in Integrative Antenatal Care: Challenges and Opportunities
Abstract Views :210 |
PDF Views:0
Authors
Rama Vaidya
1,
Madhura Kulkarni
1,
Kalpana Dhuri-Shah
1,
Nutan Nabar
1,
Jayashree Joshi
1,
Sujata Jagatap
1,
Deepak Dave
1,
Ashwinikumar Raut
1,
Hemant Paradkar
1,
Jaya Gogate
1,
Susan Sodder
1,
Ashok Vaidya
1
Affiliations
1 Kasturba Health Society-Medical Research Center, 17, KD Road, Vile Parle (W), Mumbai 400056, IN
1 Kasturba Health Society-Medical Research Center, 17, KD Road, Vile Parle (W), Mumbai 400056, IN
Source
The Indian Practitioner, Vol 70, No 10 (2017), Pagination: 11-16Abstract
No Abstract.- Relevance of Fast Track Integrative Approaches for the Control of COVID-19
Abstract Views :190 |
PDF Views:1
Authors
Affiliations
1 Managing Director, Pharmanza Herbal Pvt. Ltd. Gujarat, IN
2 CEO, Synergia Life Sciences Pvt. Ltd. Mumbai, IN
3 Director, Division of Endocrine and Metabolic Disorders, Medical and Research Centre - Kasturba Health Society, Mumbai, IN
4 Research Director, Kasturba Health Society-Medical Research Centre, Mumbai, IN
1 Managing Director, Pharmanza Herbal Pvt. Ltd. Gujarat, IN
2 CEO, Synergia Life Sciences Pvt. Ltd. Mumbai, IN
3 Director, Division of Endocrine and Metabolic Disorders, Medical and Research Centre - Kasturba Health Society, Mumbai, IN
4 Research Director, Kasturba Health Society-Medical Research Centre, Mumbai, IN
Source
The Indian Practitioner, Vol 73, No 5 (2020), Pagination: 44-47Abstract
The current global pandemic of COVID-19 has spread over 212 countries with marked morbidity and substantial mortality. This has resulted in colossal burden on the worldwide healthcare system. Globally the management of this new disease is primarily supportive and resuscitative. Vaccine and anti-COVID-19 drugs are still under development. Oriental medicine of India and China and the medicinal plants offer a potential for a fast track development of phytopharmaceuticals. In the present overview we have shortlisted the following Indian medicinal plants, based on their traditional usage and scientific rationale: Phyllanthus amarus Schum and Thonn., Berberis aristata DC., Swertia chirata and Androgaphis paniculata (Burm. f.). These medicinal plants and the phytoactives can be rapidly evaluated for anti-COVID-19 activity through reverse pharmacology.Keywords
COVID-19, Reverse Pharmacology, Medicinal Plants, Antiviral Activity, Phytopharmaceuticals.References
- COVID-19 situation update worldwide, as of 12 May 2020. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases
- Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020; 44:e40. https://doi.org/10.26633/RPSP.2020.40
- Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- an update on the status. Military Medical Research. 2020; 7:11.
- Li Y, Liu X, Guo L, Li J, Zhong D et al. Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and metaanalysis. Syst Rev. 2020; 9:75.
- Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020; 4:CD013574.
- Tillu G, Chaturvedi S, Chopra A and Patwardhan B. Public Health Aprroach of Ayurveda and Yoga for COVID-19 prophylaxis. J Alteren Complim Med. 2020; 10:1-5.
- Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, Liu JP. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integr Med. 2020 Apr; 26(4):243-250.
- Nikhat S, Fazil M. Overview of COVID-19; its prevention and management in the light of Unani medicine. Sci Total Environ. 2020 Apr 22; 728:138859.
- Vaidya AB, Roy A, Chagutur R. How to rekindle drug discovery process through integrative therapeutic targeting? Expert Opin Drug Discov. 2018; 13(10):893-898.
- Sharma SK, Sheela MA. Pharmacognostic evaluation of leaves of certain Phyllanthus species used as a botanical source of Bhumyamalaki in Ayurveda.Ayu. 2011; 32:250-253.
- Patel JR, Tripathi P, Sharma V, Chauhana NS, Dixit VK. Phyllanthus amarus: Ethnomedicinal uses, phytochemistry and pharmacology: a review. J Ethnopharmacol. 2011; 138:286-313.
- Venkateswaran PS, Millman I, Blumberg BS. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA. 1987; 84(1):274-8.
- Doshi JC, Vaidya AB, Antarkar DS, Deolalikar R, Antani DH. A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen. Indian J Gastroenterol.1994; 13(1):7-8.
- Notka F, G.R. Meiera GR, Wagner R. Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. Antiviral Res. 2003; 58(2):175–18.
- Choi J, Kim YS, Kim JH, Hwan-Suck Chung HS. Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition. Scientific Reports. 2019; 9(1):1-12.
- Harikumar KB, Kuttan G, Kuttan R. Inhibition of Viral Carcinogenesis by Phyllanthusamarus. Integrative Cancer Therapies. 2009; 8:254-25.
- Bhava Mishra, Bhavprakash nighantu. The Vidyotini Hindi commentary. Ed. By Bhavshankar Mishra and Rupali Vaisya; Chaukhamba Sanskrit Sansthan. Pg no 118-120.
- Enkhtaivan G, Muthuraman P, Kim DH, Mistry B. Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. Bioorg Med Chem. 2017; 25:5185-5193.
- Yan YQ, Fu YJ, Wu S, Qin HQ, Xiao Zhen X et al. Anti‐influenza activity of berberine improves prognosis by reducing viral replication in mice. Phytotherapy Research. 2018; 32:25602567.
- Wang Q, Qi J, Hu R, Chen Y, Kijlstra A, Yang P. Effect of berberine on pro inflammatory cytokine production by ARPE-19 cells following stimulation with tumor necrosis factor-α. Invest Ophthalmol Vis Sci. 2012; 53:2395-2402.
- Kumar R, Nair V, Gupta YK, Singh S, Arunraja S. Berberis aristata Ameliorates Adjuvant Induced Arthritis by Inhibition of NF-κB and Activating Nuclear Factor-E2related Factor 2/hem Oxygenase (HO)-1 Signaling Pathway. Immunol Invest. 2016; 45(6):473-489.
- Chunekar KC. Hindi Commentary on Bhavprakash Nighantu by Bhavamishra. Edited by Pandey GS. Choukhambha Bharati Academy, Varanasi. Reprint. 2018:70.
- Verma H, Patil P R, Kolhapure R M, Gopalkrishna V. Antiviral activity of the Indian medicinal plant extract, Swertia chirata against herpes simplex viruses: A study by in-vitro and molecular approach. Indian J Med Microbiol. 2008; 26:322-326.
- Zhou NJ, Geng CA, Huang XY, Ma YB, Zhang XM et al. Antihepatitis B virus active constituents from Swertia chirayita. Fitoterapia. 2015; 100:27–34.
- Chunekar KC. Hindi Commentary on Bhavprakash Nighantu by Bhavamishra. Edited by Pandey GS. Choukhambha Bharati Academy, Varanasi. Reprint. 2018:73.
- Vaidya BG. Nigantu Adarsha,Vol. II, edn. Varanasi: Chaukhambha Bharati Academy; 2009:229-230.
- Ramsey C, Kumar A. H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. Curr Opin Crit Care. 2011; 17:64-71.
- Chen JX, Xue HJ, Ye WC, Fang BH, Liu YH, Yuan SH et al. Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. Biol Pharm Bull. 2009; 32:1385-1391.
- Chao W, Lin B. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chin Med. 2010; 5:17. https://doi.org/10.1186/1749-8546-5-17.
- Jayakumar T, Hsieh CY, Lee JJ, Sheu JR. Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide. Evid Based Complement Alternat Med. 2013; 2013:846740.
- Bhatt A. Clinical trials during the COVID-19 pandemic: Challenges of putting scientific and ethical principles into practice. Perspect Clin Res. 2020; 11:59-63.
- Trans-system Epidemiology for Public Health to Promote an Effective One Health System for India
Abstract Views :133 |
PDF Views:0
Authors
Affiliations
1 Director, Division of Endocrine and Metabolic Disorders, Kasturba Health Society, Medical Research Centre, Mumbai. (Former Deputy Director ICMR-NIRRH Mumbai), IN
2 Secretary, Jeevaniya Society & Member National Advisory Committee, Ministry of AYUSH, GOI (Former Dy Director, CSIR-CDRI, Lucknow), IN
3 Professor Emeritus, (Former Research Director) Medical Research Centre - Kasturba Health Society, Mumbai, IN
1 Director, Division of Endocrine and Metabolic Disorders, Kasturba Health Society, Medical Research Centre, Mumbai. (Former Deputy Director ICMR-NIRRH Mumbai), IN
2 Secretary, Jeevaniya Society & Member National Advisory Committee, Ministry of AYUSH, GOI (Former Dy Director, CSIR-CDRI, Lucknow), IN
3 Professor Emeritus, (Former Research Director) Medical Research Centre - Kasturba Health Society, Mumbai, IN
Source
The Indian Practitioner, Vol 74, No 9 (2021), Pagination: 33-35Abstract
India has officially accepted pluralistic systems of medicine that include conventional medicine and the other AYUSH systems of medicine. Study of epidemiology and public health are often neglected in medical curricula of all the systems of medicine in India. It is essential to initiate endeavour for establishing trans-system epidemiology for health policy and its effective implementation. We present perspective for such an endeavour.Keywords
No KeywordsReferences
- Shetty D. Transform Indian Health Care: How the government can build, at no cost, 300 new” Medical Colleges” and offer 30,000 new seats. The Times of India, Mumbai, June 14, 2019. https://timesofindia.indiatimes.com/blogs/toi-editpage/transform-indian-healthcare-how-the-governmentcanbuild-at-no-cost-300-new-medical-colleges-and-offer30000-new-seats/
- From HinduBusiness line Kochi | Updated on December 11, 2020 https://www.thehindubusinessline.com/news/centreto-formulate-one-nation-one-health-system-policy-by2030-minister/article33305905.ece
- Antia NH, Vaidya AB, Mehrotra NN, The Indian Practitioner, 2021;Vol.74. No.9,33-35
- Vaidya AB. Effective Integration of Indian Systems of Medicine in Health Care Delivery: People’s participation, Access and Choice in a Pluralistic Democracy. In NCMH Background papers, Financing and Delivery of Health Care Services in India. New Delhi: Government of India. 2005; 7787.
- Vaidya RA, Vaidya ADB, Patwardhan B, Tillu G, Rao Y. Ayurvedic Pharmacoepidemiology: A proposed New Discipline. JAPI.2003;51:528.
- Shweta AS, Priya R. Status & Role of AYUSH and Local Health Traditions under the NRHM, NHSRC Study. 2010.
- Kotecha R, Personal communication “The Intersystem Dialogue on India-specific Guidelines for Management of Polycystic Ovarian Syndrome (PCOS): Perspective of Siddha System of Medicine”.
- Knowledge and Management Practices About Polycystic Ovarian Syndrome Among Health Care Providers in Mumbai, India: A Cross-Sectional Study
Abstract Views :98 |
PDF Views:0
Objectives: To assess knowledge about PCOS diagnosis and management by Dermatologists, Gynecologists, Endocrinologists and Family Physicians (FPs).
Methods: This cross-sectional study was done among 529 health care providers (HCPs) practicing in Mumbai metropolitan region using a convenient sample. A self-administered pretested questionnaire was filled by the HCPs after obtaining informed consent. Pearson’s Chi-square test and Analysis of Variance (ANOVA) was used to study the differences within each group.
Results: All HCPs reported that women with PCOS consulted them with a varied spectrum of symptoms. Among FPs, Allopaths had better knowledge about diagnosis and Homeopaths were more confident about PCOS management. Among Specialists, Endocrinologists were more stringent in diagnosing cases as per defined criteria, along with screening and comprehensive management of the metabolic syndrome. Although the need for multidisciplinary management was perceived, in practice holistic management was not common.
Conclusions: This study reveals the need for training and disseminating algorithms for comprehensive PCOS management across disciplines. It highlights women’s preferences in seeking health care for symptom complex of PCOS. These findings would help health policymakers to develop community-based awareness modules and India-specific management guidelines for early screening and a continuum of care for PCOS patients.
Authors
Beena Joshi
1,
Gazala Hasan
2,
Gulrez Tyebkhan
3,
Shobha Udipi
4,
Anushree Patil
5,
Duru Shah
6,
Madhuri Patil
7,
Roda Dalal
8,
Rama Vaidya
9
Affiliations
1 Scientist F, Department of Operational Research, ICMR-National Institute for Research in Reproductive Health, Mumbai, IN
2 Senior Research Fellow, Department of Operational Research, ICMR-National Institute for Research in Reproductive Health, Mumbai, IN
3 Hon Consultant Dermatologist, Medical Research Centre-Kasturba Health Society; Hon Dermatologist, Saifee Hospital, Mumbai, IN
4 Hon Director Integrative Nutrition and Ayurceuticals, Medical Research Centre-Kasturba Health Society, Mumbai, IN
5 Scientist D, Department of Clinical Research, ICMR- National Institute for Research in Reproductive Health, Mumbai, IN
6 President, PCOS Society, India. Scientific Director, Gynaecworld Assisted Fertility Center, Mumbai, IN
7 Vice-President, PCOS Society, India; Clinical Director, Dr. Patil’s Fertility and Endoscopy Clinic, Bengaluru, IN
8 Hon Editorial Consultant and Communications Associate, Medical Research Centre-Kasturba Health Society, Mumbai, IN
9 Director, Division of Endocrine and Metabolic Disorders, Medical Research Centre-Kasturba Health Society, Mumbai, IN
1 Scientist F, Department of Operational Research, ICMR-National Institute for Research in Reproductive Health, Mumbai, IN
2 Senior Research Fellow, Department of Operational Research, ICMR-National Institute for Research in Reproductive Health, Mumbai, IN
3 Hon Consultant Dermatologist, Medical Research Centre-Kasturba Health Society; Hon Dermatologist, Saifee Hospital, Mumbai, IN
4 Hon Director Integrative Nutrition and Ayurceuticals, Medical Research Centre-Kasturba Health Society, Mumbai, IN
5 Scientist D, Department of Clinical Research, ICMR- National Institute for Research in Reproductive Health, Mumbai, IN
6 President, PCOS Society, India. Scientific Director, Gynaecworld Assisted Fertility Center, Mumbai, IN
7 Vice-President, PCOS Society, India; Clinical Director, Dr. Patil’s Fertility and Endoscopy Clinic, Bengaluru, IN
8 Hon Editorial Consultant and Communications Associate, Medical Research Centre-Kasturba Health Society, Mumbai, IN
9 Director, Division of Endocrine and Metabolic Disorders, Medical Research Centre-Kasturba Health Society, Mumbai, IN
Source
The Indian Practitioner, Vol 74, No 7 (2021), Pagination: 15-22Abstract
Background: Polycystic Ovary Syndrome (PCOS) diagnosis is very complex and due to overlapping presentation of symptoms, women with PCOS may approach various practitioners, who might be using varied definitions to diagnose and manage PCOS.Objectives: To assess knowledge about PCOS diagnosis and management by Dermatologists, Gynecologists, Endocrinologists and Family Physicians (FPs).
Methods: This cross-sectional study was done among 529 health care providers (HCPs) practicing in Mumbai metropolitan region using a convenient sample. A self-administered pretested questionnaire was filled by the HCPs after obtaining informed consent. Pearson’s Chi-square test and Analysis of Variance (ANOVA) was used to study the differences within each group.
Results: All HCPs reported that women with PCOS consulted them with a varied spectrum of symptoms. Among FPs, Allopaths had better knowledge about diagnosis and Homeopaths were more confident about PCOS management. Among Specialists, Endocrinologists were more stringent in diagnosing cases as per defined criteria, along with screening and comprehensive management of the metabolic syndrome. Although the need for multidisciplinary management was perceived, in practice holistic management was not common.
Conclusions: This study reveals the need for training and disseminating algorithms for comprehensive PCOS management across disciplines. It highlights women’s preferences in seeking health care for symptom complex of PCOS. These findings would help health policymakers to develop community-based awareness modules and India-specific management guidelines for early screening and a continuum of care for PCOS patients.
Keywords
Polycystic ovary syndrome, healthcare providers, knowledge assessment, practice, managementReferences
- Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014; 2014:719050. Epub 2014 Jan 28.
- Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. Erratum in: Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added].
- Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011 Aug;24(4):223-7. Epub 2011 May 19.
- Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metab. 2014 May;18(3):317-24.
- Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017 Jun;107(6):1380-1386.e1. Epub 2017 May 5.
- Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017 Feb 1;102(2):604-612.
- Piltonen TT, Ruokojärvi M, Karro H, Kujanpää L, MorinPapunen L, Tapanainen JS, et al. Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe. PLoS One. 2019 Dec 26;14(12): e0226074.
- Blackshaw LCD, Chhour I, Stepto NK, Lim SS. Barriers and Facilitators to the Implementation of Evidence-Based Lifestyle Management in Polycystic Ovary Syndrome: A Narrative Review. Med Sci (Basel). 2019 Jun 27;7(7):76.
- Arasu A, Moran LJ, Robinson T, Boyle J, Lim S. Barriers and Facilitators to Weight and Lifestyle Management in Women with Polycystic Ovary Syndrome: General Practitioners’ Perspectives. Nutrients. 2019 May 7;11(5):1024.
- Lin AW, Bergomi EJ, Dollahite JS, Sobal J, Hoeger KM, Lujan ME. Trust in Physicians and Medical Experience Beliefs Differ Between Women With and Without Polycystic Ovary Syndrome. J Endocr Soc. 2018 Aug 1;2(9):1001-1009.
- Geense WW, van de Glind IM, Visscher TL, van Achterberg T. Barriers, facilitators and attitudes influencing health promotion activities in general practice: an explorative pilot study. BMC Fam Pract. 2013 Feb 9; 14:20.
- Rodgers RJ, Avery JC, Moore VM, Davies MJ, Azziz R, Stener-Victorin E, et al. Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. 2019 Mar;8(3): R71-R75.
- Asante A, Omurtag K, Stewart EA, Coddington CC. Screening for Insulin Resistance in Polycystic Ovary Syndrome: Views of Physician Members of the American Society for Reproductive Medicine. J Reprod Med. 2015 SepOct;60(9-10):371-7.
- Doll I, Doll R, Buhling KJ. Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature. Arch Gynecol Obstet. 2012 Mar;285(3):689-97. Epub 2011 Aug 10.
- Conway G, Dewailly D, Diamanti-Kandarakis E, EscobarMorreale HF, Franks S, Gambineri A, et al. ESE PCOS Special Interest Group. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group’s Questionnaire. Eur J Endocrinol. 2014 Oct;171(4):489-98. Epub 2014 Jul 21.
- Charifson MA, Trumble BC. Evolutionary origins of polycystic ovary syndrome: An environmental mismatch disorder. Evol Med Public Health. 2019 Mar 26;2019(1):50-63.
- Hillman JK, Johnson LN, Limaye M, Feldman RA, Sammel M, Dokras A. Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS [corrected]. Fertil Steril. 2014 Feb;101(2):530-5. Epub 2013 Dec 30. Erratum in: Fertil Steril. 2014 Jun;101(6):1791.
- Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012 Nov-Dec;18(6):618-37. Epub 2012 Jul 4.
- Goyal M, Dawood AS. Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review. J Hum Reprod Sci. 2017 Jul-Sep;10(3):154-161.
- Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. Epub 2018 Jul 19.
- Ding T, Baio G, Hardiman PJ, Petersen I, Sammon C. Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study. BMJ Open. 2016 Jul 11;6(7): e012461
- Teede H, Gibson-Helm M, Norman RJ, Boyle J. Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome. J Clin Endocrinol Metab. 2014 Jan;99(1): E107-11. Epub 2013 Dec 20.
- Lin AW, Bergomi EJ, Dollahite JS, Sobal J, Hoeger KM, Lujan ME. Trust in Physicians and Medical Experience Beliefs Differ Between Women With and Without Polycystic Ovary Syndrome. J Endocr Soc. 2018 Aug 1;2(9):1001-1009.
- ABHIYAAN PCOS, A Consortium for Multidisciplinary Strategy for Management
Abstract Views :98 |
PDF Views:0
Authors
Affiliations
1 Hon Consultant Dermatologist, Medical Research Centre- Kasturba Health Society, Mumbai, India. Hon Dermatologist, Saifee Hospital, Mumbai, IN
2 Scientist F, Department of Operational Research, ICMR-National Institute for Research in Reproductive Health, Mumbai, IN
3 Director, Division of Endocrine and Metabolic Disorders,Medical Research Centre- Kasturba Health Society, Mumbai, IN
1 Hon Consultant Dermatologist, Medical Research Centre- Kasturba Health Society, Mumbai, India. Hon Dermatologist, Saifee Hospital, Mumbai, IN
2 Scientist F, Department of Operational Research, ICMR-National Institute for Research in Reproductive Health, Mumbai, IN
3 Director, Division of Endocrine and Metabolic Disorders,Medical Research Centre- Kasturba Health Society, Mumbai, IN
Source
The Indian Practitioner, Vol 74, No 7 (2021), Pagination: 41-45Abstract
Polycystic Ovary Syndrome (PCOS), a common reproductive-endocrine-metabolic disorder of women with its galloping prevalence is reaching epidemic proportions today in India and abroad. Women suffering from PCOS have a wide spectrum of clinical manifestations like irregular menstrual cycles, infertility, hirsutism, acne and vulnerability for obesity. Besides these women are at a risk for concurrently manifesting obesity and prediabetes or subsequent development of type 2 diabetes mellitus and consequent cardiovascular diseases. Some of the manifestations have caused stigmatization and social isolation of women with PCOS contributing to its adverse psycho-social impact. This multiplicity of diverse manifestations makes it difficult for the patients to choose a specialist. As a consequence, there is often a fragmented attention to PCOS from diverse specialties like dermatology, gynecology, diabetology and psychiatrist. Additionally, the less known and poorly understood etiology of PCOS have also posed a challenge for medical science for committed research, education and organized services. This is more so due to the compartmentalization and divergence into super specialization in modern medical and biomedical sciences. Recognizing PCOS as a condition of great public health issue in India, a group of committed clinical and basic scientists from four major institutes of Mumbai formed, ABHIYAAN PCOS, a consortium for a co-operative endeavor in addressing the multiple aspects that concern women with PCOS. In the present article, we have covered the ground reality of the PCOS in India, the need to develop India-specific guidelines in-view of the pluralistic healthcare and the current efforts in the domain of PCOS by both private and public health-sectors.References
- World Health Organization Regional Office for the Western. Global status report on noncommunicable diseases 2010 [Internet]. Geneva: World Health Organization; 2011 p. 164. Report No.: ISBN 978 92 4 068645 8. Available from: https://www.who.int/nmh/ publications/ncd_report_full_en.pdf
- Indian Council of Medical Research, Public Health Foundation of India, Institute for Health Metrics And Evaluation. India: Health of the Nation’s States (India State-Level Disease Burden Initiative) [Internet]. [cited 2020 May 9]. Report No.: ISBN 978-0-9976462-14. Available from: https://phfi.org/the-work/research/ the-india-state-level-disease-burden-initiative/
- Sivanantham P, Sahoo J, Lakshminarayanan S, Bobby Z, Kar SS (2021) Profile of risk factors for NonCommunicable Diseases (NCDs) in a highly urbanized district of India: Findings from Puducherry district-wide STEPS Survey, 2019–20. PLoS ONE 16(1): e0245254. https://doi.org/10.1371/journal.pone.0245254
- Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India.Indian J Med Res. 2019;150(4):333-344.
- Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metab. 2014;18(3):317-324.
- Chatterjee M, Bandyopadhyay SA. Assessment of the prevalence of polycystic ovary syndrome among the college students: A case–control study from Kolkata. J Mahatma Gandhi Inst Med Sci. 2020; 25:28-32.
- Teede HJ, Misso ML, Deeks AA, Moran LJ, Bronwyn G A Stuckey BGA et al. Assessment and management of polycystic ovary syndrome: summary of an evidencebased guideline. Med J Aust 2011; 195 (6): S65.
- Teede HJ, Misso ML, Costello MF, Dokras A, Laven J et al. International PCOS Network, Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction. 2018;33(9):1602– 1618.
- Malik S, Jain K, Talwar P, Prasad S, Dhorepatil B, Devi G et al. Management of Polycystic Ovary Syndrome in India. Fertility Science and Research 2014; Vol 1(Issue 1): 23-43.
- Multidisciplinary Opinion on Challenges in Medical Management of PCOS. An Indian Perspective. By Eminent physicians, Clinical and Basic Scientists.March 2016 Edition.
- Sharma S, Aggarwal N. Multidisciplinary opinion on challenges in the medical management of polycystic ovarian syndrome. J Mid-life Health 2017; 8:48-9.
- Joshi B, Hasan G, Tyebkhan G, Udipi S, Patil A et al. Knowledge and Management practices about Polycystic Ovarian Syndrome among Health Care Providers in Mumbai, India: a cross-sectional study. The Indian Practitioner. 2021; 74:15-22.
- Vaidya R, Pandey S, Vaidya A. Polycystic ovarian syndrome: Is it a Chronic Inflammatory Disease? ECAB Clinical Update: Obstetrics and Gynecology Elsevier Clinical Advisory panel 2008; 1:42-73.
- Vaidya RA. Maitreyi: An Initiative for Comprehensive Health-Care Programme for Menopausal Women. The Indian Practitioner. 2019;72(9):42-44.
- Patil A D, Vaidya A, Pathak S D, Chauhan L, Surve S et al. Yoga Therapy: The Fourth Dimension in the Multidisciplinary Management of Women with Polycystic Ovary Syndrome, A Narrative Review. The Indian Practitioner. 2018; 71:45-51.
- Breast Cancer: A Ticking Time Bomb
Abstract Views :79 |
PDF Views:0
Authors
Kanchan Kaur
1,
Rama Vaidya
2
Affiliations
1 Senior Director Breast Surgery, Medanta, The Medicity Hospital-Gurgaon, IN
2 Director, Division of Endocrine and Metabolic Disorders and Secretary‑Research & Administrative Council, Kasturba Health Society-Medical Research Centre, Mumbai, IN
1 Senior Director Breast Surgery, Medanta, The Medicity Hospital-Gurgaon, IN
2 Director, Division of Endocrine and Metabolic Disorders and Secretary‑Research & Administrative Council, Kasturba Health Society-Medical Research Centre, Mumbai, IN
Source
The Indian Practitioner, Vol 75, No 10 (2022), Pagination: 26-30Abstract
India has seen a galloping upward trend in the incidence of breast cancer over the past few decades. It has become the commonest cancer amongst women in the country, surpassing cervical cancer. Lack of awareness coupled with fear, misinformation, myths, and beliefs, contribute to a presentation at the late stages of the disease. The outcomes of treatment are negatively impacted by the delayed presentation and are further compounded by a fragmented healthcare system. To tackle this, a concerted large-scale effort is the urgent need of the hour. On the one hand, we need to have persistent and consistent community-based awareness which motivates preventive and early health-seeking behaviour amongst women. On the other hand, planned and streamlined services for cancer care consisting of well-established qualitative infrastructure along with trained experts need to be developed so as to provide accessible, affordable, and standardized screening for early detection and treatment of breast cancer. Attention also needs to be paid to issues not directly linked to cancer treatment, but arising from it such as fertility preservation in young women diagnosed with breast cancer and the comprehensive care for breast cancer survivors.Keywords
breast cancer, India, the healthcare gaps, early detection and screening, bridge model of healthcare.References
- International Agency for Research on Cancer. India Source: Globocan 2020. [cited 11 June 2021] Available from:https:// gco.iarc.fr/today/data/factsheets/populations/356-indiafact- sheets.pdf
- Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D. BRCA1 and BRCA2 inIndian breast cancer patients. Hum Mutat.2002;20:473-474.
- Leong SP, Shen ZZ, Liu TJ et al: Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308-2324.
- Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007;31:1031–40.
- IARC Working Group on the Evaluation of Cancer- Preventive Strategies. Breast Cancer Screening. Vol 15. IARC Press; 2016.
- Njor S, Nystrom L, Moss S, et al; Breast cancer mortality in mammographic screening in Europe: a review of incidencebased mortality studies. (Euroscreen Working Group). J Med Screen. 2012;19(1):33-41.
- Duffy SW, Tabár L, Yen AM-F, Dean PB, Smith RA, Jonsson H, Törnberg S et al. Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women. Cancer. 2020;126(13):2971-2979.
- Søren R Christiansen, Philippe Autier, Henrik Støvring, Change in effectiveness of mammography screening with decreasing breast cancer mortality: a population-based study. European Journal of Public Health. 2022;32(4):630–635.
- Gøtzsche PC. Mammography screening is harmful and should be abandoned. J R Soc Med. 2015 Sep;108(9):341-5. DOI: 10.1177/0141076815602452. PMID: 26359135; PMCID: PMC4582264.
- Mittra I, Mishra GA, Dikshit RP, Gupta S, Kulkarni VY, Shaikh HKA, Shastri SS, Hawaldar R, Gupta S, Pramesh CS, Badwe RA. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ. 2021;372:n256.
- National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke: Operational Guidelines. Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Accessed June 1, 2021. https://main.mohfw.gov.in/ sites/default/files/Operational%20Guidelines%20of%20 NPCDCS%20%28Revised%20-%202013-17%29_1.pdf
- Kumar S, Usmanova G, Nair TS, Srivastava VK, Singh R, Mohanty N et al. Implementation of a large-scale breast cancer early detection program in a resource-constrained setting: real-world experiences from 2 large states in India. Cancer. 2022;128(9):1757-1766.
- Screening of Diabetic Patients for Non-Alcoholic Fatty Liver Disease Based on Liver Indices: A Retrospective Cross-Sectional Study
Abstract Views :54 |
PDF Views:0
Authors
Affiliations
1 Senior Research Fellow, Kasturba Health Society Medical Research Centre (KHS-MRC), IN
2 Physician, KHS-MRC, IN
3 Director-Integrative Medicine and Clinical Research, KHS-MRC, IN
4 Director-Division of Endocrinology, KHS-MRC, IN
1 Senior Research Fellow, Kasturba Health Society Medical Research Centre (KHS-MRC), IN
2 Physician, KHS-MRC, IN
3 Director-Integrative Medicine and Clinical Research, KHS-MRC, IN
4 Director-Division of Endocrinology, KHS-MRC, IN
Source
The Indian Practitioner, Vol 76, No 2 (2023), Pagination: 21-25Abstract
Background and Aims: Non-Alcoholic Fatty Liver Disease (NAFLD) includes a wide spectrum of liver pathophysiology, ranging between relatively benign Nonalcoholic fatty liver to a serious pathology like fibrosis and cirrhosis. NAFLD is commonly associated with Type 2 Diabetes Mellitus (T2DM) and Metabolic Syndrome and may increase the risk for mortality. American Diabetes Association and European Association for the study of Diabetes have recommended screening of all T2DM patients for NAFLD.
Materials and Methods: We did a retrospective analysis of medical records of T2DM patients who attended a diabetes clinic as ambulant patients for 1 year. Out of 215 patients, complete demographic, haemodynamic and biochemical data was available for 46 patients. Simple liver indices like Hepatic Steatosis Index (HSI) and Fibrosis score (FIB-4) were computed.
Results: Presence of steatosis was observed in30 patients based on HSI > 36. Out of these, intermediate risk of advanced fibrosis was observed in 4 patients based on FIB-4 > 1.3.
Conclusion: HSI based screening for steatosis and FIB-4 based screening for fibrosis should be part of liver monitoring in patients with type 2 diabetes mellitus to identify individuals with higher risk for NAFLD.
Keywords
Hepatic Steatosis Index, Fibrosis Score, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.References
- Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J. Ophthalmol 2021; 69:2932-8.
- Mitra S. Diabetes Research, Prevalence, and Intervention in India. European Journal of Environment and Public Health 2019, 3(1), 1-5. Available at, http://dx.doi.org/10.20897/ejeph/4004
- Dharmalingam M and Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Indian J Endocrinol Metab. 2018; 22(3): 421-428.doi: 10.4103/ijem.IJEM_585_17, PMCID: PMC6063173PMID: 30090738
- Weiti Wu, Jingjing Xiang, Xiaoye Chen, Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals with Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. 2021; 12:773342, doi: 10.3389/fendo.2021.773342, PMID: 34992579, PMCID: PMC8724262
- De A, Duseja A, Nonalcoholic Fatty Liver Disease: Indian Perspective. Clinical Liver Disease September 2021; 18 (3): 158-163.
- Sumida Y, Nakajima A, Hyogo H, Tanaka S, Ono M, Fujii H, et al. Non-invasive scoring systems for predicting NASH in Japan: evidence from Japan Study Group of NAFLD. Integr Mol Med 2015: 2(2): 145-149. doi: 10.15761/IMM.1000130
- Dhamija, E, Paul, SB, Kedia, S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. The Indian journal of medical research 2019; 149(1): 9-17. https://doi.org/10.4103/ijmr.IJMR_1456_17
- Viswanathan V, Kadiri M, Medimpudi S, Kumpatla S, Association of non-alcoholic fatty liver disease with diabetic microvascular and macrovascular complications in south Indian diabetic patients. International Journal of Diabetes in Developing countries. 2010; 30(4): 208-212.
- Barbosa JV, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatology Communications 2021; 5(2):158-167. https://doi.org/10.1002/hep4.1618
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of non alcoholicfatty liver disease: a population-based cohort study. Gastroenterology2005; 129:113-21.
- Arslan U, Turkoglu S, Balcioglu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007; 18:433-6.
- Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, KimW,et al. Hepatic Steatosis Index: A simple screening tool reflectingnonalcoholic fatty liver disease. Digestive and Liver Disease 2010; 42(7): 503-508.doi: 10.1016/j.dld.2009.08.002
- Fennoun H, Mansouri SE, Tahiri M, Haraj NE, Aziz SE, Hadad F, et al. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. Pan Afr Med J. 2020; 37: 270.doi: 10.11604/pamj.2020.37.270.9087, PMCID: PMC7864273, PMID: 33598084
- Lomonaco R, LeivaEG,Bril F, Shrestha S, MansourL,Budd J et al. Advanced Liver Fibrosis IsCommon in Patients with Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021; 44:399-406 | https://doi.org/10.2337/dc20-1997
- Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. ‘FIB-4: an Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Liver Biopsy and FibroTest. Hepatology 2007; 46 (1): 32-36.
- Rinella ME. Nonalcoholic fatty liver disease: Asystematic Review. JAMA, 2015; 313: 2263-73.
- Nanji AA, French SW, Freeman JB. Serum alanine amino transferase to aspartate amino transferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986; 36: 266-9.
- Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P et al. Development and validation of the Framingham Steatosis index to identify persons with hepatic steatosis. Clin Gastroenterol Hepatol, 2016; 14: 1072-1180.
- Ken Liu K, Xu W, Vincent Wai-Sun Wong. Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet? Hepatology. 2017; 65(1): 8-11. doi: 10.1002/hep.28840. PMID: 27639247 DOI: 10.1002/hep.28840
- Sberna AL, B. Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Verges B, Hillon P, Petit M. European Association for the Study of the Liver (EASL),European Association for the Study of Diabetes (EASD),and European Association for the Study of Obesity (EASO), clinical practice recommendations for the managementof non-alcoholic fatty liver disease: evaluation of their application in peoplewithType2diabetes.https://www.researchgate.net/profile/Jean-Michel-Petit/publication/321862648_ Diabet. Med. 00: 000–000 (2018)
- Shah AG, LydeckerA, Murray K, Tetri BN, ContosMJ, Sanyal AJ, and NASH Clinical Research Networket. Use of the fib4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 October; 7(10): 1104–1112. doi: 10.1016/j.cgh.2009.05.033.